gms | German Medical Science

International Conference on SARS - one year after the (first) outbreak

08. - 11.05.2004, Lübeck

Synthetic peptide studies on the SARS coronavirus spike Ggycoprotein: Perspective for SARS vaccine development

Talk

  • Wai-Yan Choy - Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Shu-Guang Lin - Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong, China
  • Paul Kay-Sheung Chan - Department of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong
  • John Siu-Lun Tam - Department of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Dennis Yuk-Ming Lo - Department of Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Ida Miu-Yee Chu - Department of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Sau-Na Tsai - Department of Biology, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Ming-Qi Zhong - Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Kwok-Pui Fung - Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Mary Miu-Yee Waye - Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Stephen Kwok-Wing Tsui - Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Kai-On Ng - Department of Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Zhi-Xin Shan - Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong, China
  • Min Yang - Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong, China
  • Zhan-Yi Lin - Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong, China
  • corresponding author Sai-Ming Ngai - Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong. Department of Biology, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Yi-Long Wu - Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong, China

International Conference on SARS - one year after the (first) outbreak. Lübeck, 08.-11.05.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04sars3.03

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/sars2004/04sars016.shtml

Veröffentlicht: 26. Mai 2004

© 2004 Choy et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: The S (spike) protein of the etiologic coronavirus agent of the severe acute respiratory syndrome (SARS) plays a central role in mediating viral infection via receptor binding and membrane fusion between the virion and the host cell. We focused on using synthetic peptides for developing antibodies against SARS-CoV, which aimed to block viral invasion by eliciting an immune response specific to the native SARS-CoV S protein.

Methods: Six peptide sequences corresponding to the surface regions of SARS-CoV S protein were designed and investigated using combined bioinformatics and structural analysis. These synthetic peptides were used to immunize both rabbits and monkeys. Antisera collected one week after the second immunization were analyzed by ELISA and tested for antibody specificity against SARS-CoV by immunofluorescent confocal microscopy.

Results: Four of our six synthetic peptides (namely S2, S3, S5 and S6) elicited SARS-CoV-specific antibodies, from which S5 (residues 788-820) and S6 (residues 1002-1030) exhibited similar immunogenic responses as compared with a parallel investigation employing truncated recombinant protein analogs of the SARS-CoV S protein. This suggested that our S5 and S6 peptides may represent two minimum biologically active sequences of the immunogenic regions of the SARS-CoV S protein.

Conclusions: Synthetic peptides can elicit specific antibodies to SARS-CoV. The study provides insights for the future development of SARS vaccine via the synthetic peptide-based approach.


References

1.
Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76
2.
Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66
3.
Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-25
4.
Siddell S, Wege H, Ter Meulen V. The biology of coronaviruses. J Gen Virol 1983;64:761-76
5.
Makela MJ, Puhakka T, Ruuskanen O, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol 1998;36:539-42
6.
Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394-9
7.
Marra MA, Jones SJ, Astell CR, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003;300:1399-404
8.
Thiel V, Ivanov KA, Putics A, et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol 2003;84:2305-15
9.
Cavanagh D. The coronavirus surface glycoprotein. In: Siddell SG, ed: The Coronaviridae. New York: Plenum Press, 1995:73-113
10.
Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viral entry and pathogenesis. Virology 2001;279:371-4
11.
Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 2003;77:8801-11
12.
Hodges RS, Burke TWL, Mant CT, Ngai SM. Preparative reversed-phase gradient elution chromatography on an analytical column. In: Mant CT, Hodges RS, eds. High performance liquid chromatography of peptides and proteins: separation, analysis and conformation. Boca Raton, FL: CRC Press, 1991:773-82
13.
Ng EK, Hui DS, Chan KC, Hung EC, Chiu RW, Lee N, et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem 2003;49:1976-80
14.
Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003;423:240
15.
Crowther JR. The ELISA guidebook, 1st ed. Totowa: Humana Press Inc, 2001:167-8